Cory Iverson - Concepedia

Author

Cory Iverson

Roswell Park Comprehensive Cancer Center

Also Known As

C. Iverson, C. N. M. Iverson, Christopher Iverson, Cory Iverson

Publications

761

Citations

H-Index

Concepts

All Affiliations

Roswell Park Comprehensive Cancer Center

About

Cory Iverson is an author at Roswell Park Comprehensive Cancer Center specializing in medicine, cell signaling, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	454
2	Cell Biology	2	2	443
3	Health Sciences	1	1	182
4	Natural Sciences	1	1	261
5	Molecular Biology	1	1	261

Cory Iverson

Publications

733

Citations

H-Index

Page 1

	Year	Citations
TOR Complex 1 Includes a Novel Component, Tco89p (YPL180w), and Cooperates with Ssd1p to Maintain Cellular Integrity in Saccharomyces cerevisiae Scott Anderson, J. Michael McCaffery, John R. Yates, Journal of Biological Chemistry Distinct Protein ComplexesMolecular BiologyMolecular GeneticsMolecular ResearchYeast	2004	261
RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer Cory Iverson, Gary Larson, Chon Lai, Cancer Research Chemoprevention StrategyCell ProliferationTumor BiologyOncologyReceptor Tyrosine Kinase	2009	182
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney Jeffrey N. Miner, Philip K. Tan, David Hyndman, Arthritis Research & Therapy	2016	124
Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer Colin D. Weekes, Daniel D. Von Hoff, Alex A. Adjei, Clinical Cancer Research	2013	58
The relationship between ferritin and urate levels and risk of gout Tahzeeb Fatima, Cushla McKinney, Tanya J. Major, Arthritis Research & Therapy	2018	46
Omega-3-carboxylic acids provide efficacious anti-inflammatory activity in models of crystal-mediated inflammation Cory Iverson, Andrew Bacong, Sha Liu, Scientific Reports	2018	31
A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer Alex A. Adjei, Donald Richards, Anthony B. El-Khoueiry, Clinical Cancer Research	2015	20
Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer. Lia Gore, Kriste A. Lewis, Daniel D. Von Hoff, Journal of Clinical Oncology Tumor BiologyAdvanced CancerOncologyGastrointestinal OncologyTumor Perk	2011	11

Page 1